Xenon (XP0) Price & Analysis

Compare

0 Followers

XP0 Stock Chart & Stats

Day’s Range― - ―

52-Week Range€25.00 - €42.40

Previous CloseN/A

Volume0.00

Average Volume (3M)10.00

Market Cap

€2.50B

Enterprise Value€1.99B

Total Cash (Recent Filing)€487.55M

Total Debt (Recent Filing)€8.71M

Price to Earnings (P/E)―

Beta0.45

Next Earnings

Nov 05, 2025

EPS Estimate

-0.98

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.91

Shares Outstanding77,105,800

10 Day Avg. Volume0

30 Day Avg. Volume10

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€46.49

Price Target Upside49.97% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering12

Bulls Say, Bears Say

Bulls Say

Clinical MilestoneThe enrollment completion of the Phase 3 X-TOLE2 study marks a key milestone for azetukalner.

Financial PositionThe company ended the quarter with approximately $625 million in cash, which management believes should fund operations into 2027.

Market PositionAzetukalner is the leading novel therapy candidate for focal epilepsy, and data from the X-TOLE and X-TOLE2 studies are sufficient for NDA submission in 2026.

Bears Say

CompetitionPotential competition from BioHaven Pharmaceuticals with its Kv7 channel modulator, BHV-7000, which is expected to readout results in focal onset epilepsy in 1H26.

Investment And DevelopmentFurther investment and patience are required for azetukalner, despite its strong Phase 2b data and differentiated mechanism.

Regulatory ChallengesThe Phase III X-ACKT clinical study of azetukalner in PGTCS continues to enroll patients and is intended to support regulatory submissions for an additional epilepsy indication.

Xenon News

Xenon Pharmaceuticals assumed with an Overweight at Wells Fargo

Wells Fargo assumed coverage of Xenon Pharmaceuticals (XENE) with an Overweight rating and $48 price target The company...

27d ago

XENE

Xenon Pharmaceuticals to Host Investor Webinar on Non-Opioid Pain Treatments

An update from Xenon ( ($XENE) ) is now available. Xenon Pharmaceuticals announced an upcoming investor webinar to...

4d ago

XENE

Xenon Pharmaceuticals’ Earnings Call Highlights Progress and Promise

Xenon Pharmaceuticals (($XENE)) has held its Q2 earnings call. Read on for the main highlights of the call....

29d ago

XENE

Xenon Pharmaceuticals Issues Equity Inducement Grants to New Employees

Xenon ( ($XENE) ) just unveiled an update. Xenon Pharmaceuticals announced the issuance of equity inducement grants to...

1M ago

XENE

Xenon: Promising Outlook with Strong Financial Health and Expanding Research Initiatives

In a report released on August 11, Marc Goodman from Leerink Partners reiterated a Buy rating on Xenon,...

2M ago

XENE

Xenon Pharmaceuticals price target lowered to $55 from $57 at RBC Capital

RBC Capital analyst Brian Abrahams lowered the firm’s price target on Xenon Pharmaceuticals (XENE) to $55 from $57...

2M ago

XENE

Xenon’s Promising Pipeline and Strategic Progress Justify Buy Rating

In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Xenon, with a...

2M ago

XENE

Xenon Pharmaceuticals: Promising Clinical Developments and Strategic Positioning Support Buy Rating

Xenon, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Serge Belanger from Needham...

2M ago

XENE

Xenon Pharmaceuticals: Promising Clinical Pipeline and Strategic Progress Justify Buy Rating

William Blair analyst Myles Minter has reiterated their bullish stance on XENE stock, giving a Buy rating yesterday....

2M ago

XENE

Xenon Pharmaceuticals Reports Q2 2025 Progress and Outlook

Xenon Pharmaceuticals ( ($XENE) ) has released its Q2 earnings. Here is a breakdown of the information Xenon...

2M ago

XENE

Xenon Completes Patient Recruitment for Phase 3 Study

Xenon ( ($XENE) ) has shared an update. Xenon Pharmaceuticals reported its second quarter 2025 financial results and...

2M ago

XENE

Xenon Pharmaceuticals reports Q2 EPS $1.07 vs. (75c) last year

Cash and cash equivalents and marketable securities were $624.8M as of June 30, compared to $754.4M as of...

2M ago

XENE

XENE Earnings this Week: How Will it Perform?

Xenon Pharmaceuticals (XENE) is scheduled to report 2nd quarter earnings on 08/11/2025, after the market closes. Regarding Q2...

2M ago

XENE

Citizens JMP pharmaceuticals analysts hold analyst/industry conference call

Pharmaceuticals Analysts discuss novel treatments and clinical trial design innovations in focal onset epilepsy (RAPP, XENE, NPCE) on...

3M ago

NPCE

RAPP

XP0 FAQ

What was Xenon Pharmaceuticals’s price range in the past 12 months?

Xenon Pharmaceuticals lowest stock price was €25.00 and its highest was €42.40 in the past 12 months.

What is Xenon Pharmaceuticals’s market cap?

Xenon Pharmaceuticals’s market cap is €2.50B.

When is Xenon Pharmaceuticals’s upcoming earnings report date?

Xenon Pharmaceuticals’s upcoming earnings report date is Nov 05, 2025 which is in 37 days.

How were Xenon Pharmaceuticals’s earnings last quarter?

Xenon Pharmaceuticals released its earnings results on Aug 11, 2025. The company reported -€0.915 earnings per share for the quarter, missing the consensus estimate of -€0.844 by -€0.071.

Is Xenon Pharmaceuticals overvalued?

According to Wall Street analysts Xenon Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Xenon Pharmaceuticals pay dividends?

Xenon Pharmaceuticals does not currently pay dividends.

What is Xenon Pharmaceuticals’s EPS estimate?

Xenon Pharmaceuticals’s EPS estimate is -0.98.

How many shares outstanding does Xenon Pharmaceuticals have?

Xenon Pharmaceuticals has 77,105,800 shares outstanding.

What happened to Xenon Pharmaceuticals’s price movement after its last earnings report?

Xenon Pharmaceuticals reported an EPS of -€0.915 in its last earnings report, missing expectations of -€0.844. Following the earnings report the stock price went up 6.993%.

Which hedge fund is a major shareholder of Xenon Pharmaceuticals?

Currently, no hedge funds are holding shares in DE:XP0

Xenon Stock Smart Score

Outperform

Fundamentals

Return on Equity

-37.65%

Trailing 12-Months

Asset Growth

-23.72%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Xenon (XP0) Earnings & Revenues

Historic Earnings Reports

XP0 Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a positive outlook for Xenon Pharmaceuticals, with significant progress in their epilepsy and neuropsychiatric programs, strong financial health, and promising early-stage pipeline developments. However, there are some uncertainties in the bipolar depression program and regulatory filing timeline. Overall, the positive advancements strongly outweigh the noted uncertainties.View all DE:XP0 earnings summaries

XP0 Stock 12 Month Forecast

Average Price Target

€46.49

▲(49.97% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"24":"€24","32":"€32","40":"€40","48":"€48","56":"€56"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":55.44632145,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€55.45</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":46.489607985,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€46.49</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.94497584,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€40.94</span>\n  </div></div>","useHTML":true}}],"tickPositions":[24,32,40,48,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.6,34.35740934230769,36.114818684615386,37.872228026923075,39.62963736923077,41.38704671153846,43.144456053846156,44.901865396153845,46.65927473846154,48.41668408076923,50.174093423076926,51.931502765384614,53.6889121076923,{"y":55.44632145,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.6,33.66843138346154,34.736862766923075,35.80529415038462,36.873725533846155,37.94215691730769,39.01058830076923,40.07901968423077,41.14745106769231,42.215882451153846,43.28431383461538,44.35274521807692,45.42117660153846,{"y":46.489607985,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.6,33.24192121846154,33.883842436923075,34.525763655384615,35.167684873846156,35.80960609230769,36.45152731076923,37.09344852923077,37.7353697476923,38.37729096615384,39.019212184615384,39.66113340307692,40.30305462153846,{"y":40.94497584,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":40,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.4,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.2,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.6,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.4,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.8,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.8,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >